Literature DB >> 3167093

Effect of pyridoxal isonicotinoyl hydrazone and other hydrazones on iron release from macrophages, reticulocytes and hepatocytes.

P Ponka1, D Richardson, E Baker, H M Schulman, J T Edward.   

Abstract

A model consisting of 59Fe-labelled macrophages was developed for screening potential iron-chelating drugs. Mouse peritoneal macrophages, induced by previous intraperitoneal injections of 3% thioglycollate, were labelled in vitro by their exposure to immune complexes of 59Fe-transferrin-antitransferrin antibody. Optimal conditions for macrophage labelling and subsequent 59Fe release were established. Sixty-two aromatic hydrazones, the majority of which had iron binding structures similar to pyridoxal isonicotinoyl hydrazone, were synthesized by condensation of aromatic aldehydes (pyridoxal, salicylaldehyde, 2-hydroxy-1-naphthylaldehyde and 2-furaldehyde) with various acid hydrazides prepared by systematic substitutions on the benzene ring. These compounds were examined for their potential to stimulate 59Fe release from 59Fe-labelled macrophages and also from reticulocytes and hepatocytes loaded with non-heme 59Fe. The majority of hydrazones derived from pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde seemed to be equally effective in both the macrophage and reticulocyte testing systems. However, the pyridoxal hydrazones were much more active in hepatocytes than the other groups of hydrazones. Several compounds proved to be very potent in mobilizing 59Fe. These included hydrazones derived from 2-hydroxy-1-naphthylaldehyde and benzoic acid hydrazide, p-hydroxybenzoic acid hydrazide, 2-thiophenecarboxylic acid hydrazide, and also pyridoxal benzoyl hydrazone, pyridoxal m-fluorobenzoyl hydrazone and pyridoxal 2-thiophenecarboxyl hydrazone.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3167093     DOI: 10.1016/0304-4165(88)90197-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  Pyridoxal isonicotinoyl hydrazone (PIH) prevents copper-mediated in vitro free radical formation.

Authors:  M Hermes-Lima; M S Gonçalves; R G Andrade
Journal:  Mol Cell Biochem       Date:  2001-12       Impact factor: 3.396

2.  Examination of diverse iron-chelating agents for the protection of differentiated PC12 cells against oxidative injury induced by 6-hydroxydopamine and dopamine.

Authors:  Pavlína Hašková; Lenka Applová; Hana Jansová; Pavel Homola; Katherine J Franz; Kateřina Vávrová; Jaroslav Roh; Tomáš Šimůnek
Journal:  Sci Rep       Date:  2022-06-13       Impact factor: 4.996

3.  A small molecule redistributes iron in ferroportin-deficient mice and patient-derived primary macrophages.

Authors:  Stella Ekaputri; Eun-Kyung Choi; Manuela Sabelli; Luisa Aring; Kelsie J Green; JuOae Chang; Kai Bao; Hak Soo Choi; Shigeki Iwase; Jonghan Kim; Elena Corradini; Antonello Pietrangelo; Martin D Burke; Young Ah Seo
Journal:  Proc Natl Acad Sci U S A       Date:  2022-06-22       Impact factor: 12.779

4.  Iron chelators of the pyridoxal isonicotinoyl hydrazone class. III. Formation constants with calcium(II), magnesium(II) and zinc(II).

Authors:  D R Richardson; G T Hefter; P M May; J Webb; E Baker
Journal:  Biol Met       Date:  1989

5.  Pyridoxal isonicotinoyl hydrazone and analogues. Study of their stability in acidic, neutral and basic aqueous solutions by ultraviolet-visible spectrophotometry.

Authors:  D Richardson; L W Vitolo; E Baker; J Webb
Journal:  Biol Met       Date:  1989

6.  Hepatitis E virus ORF1 encoded macro domain protein interacts with light chain subunit of human ferritin and inhibits its secretion.

Authors:  Nishant Kumar Ojha; Kavita S Lole
Journal:  Mol Cell Biochem       Date:  2016-05-12       Impact factor: 3.396

7.  Gallium (III) Complexes with 5-Bromosalicylaldehyde Benzoylhydrazones: In Silico Studies and In Vitro Cytotoxic Activity.

Authors:  Boryana Nikolova-Mladenova; Silvia Angelova; Georgi Momekov
Journal:  Molecules       Date:  2022-08-26       Impact factor: 4.927

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.